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Human Rev1 is a translesion synthesis (TLS) DNA polymerase involved in bypass replication across
sites of DNA damage and postreplicational gap-ﬁlling. Rev1 plays an essential structural role in
TLS by providing a binding platform for other TLS polymerases that insert nucleotides across DNA
lesions (polg, poli, polj) and extend the distorted primer-terminus (pol1). We use NMR spectroscopy
to demonstrate that the Rev1 C-terminal domain utilizes independent interaction interfaces to
simultaneously bind a fragment of the ’inserter’ polg and Rev7 subunit of the ’extender’ pol1,
thereby serving as a cassette that may accommodate several polymerases making them instanta-
neously available for TLS.
Structured summary of protein interactions:
REV1, REV3 and REV7 physically interact by nuclear magnetic resonance (View interaction), molecular
sieving (View interaction) and isothermal titration calorimetry (View interaction).
REV3 and REV7 bind by molecular sieving (View interaction)
REV1 and Polg-RIR peptide bind by nuclear magnetic resonance (View interaction)
REV1, REV3, REV7 and Polg-RIR peptide physically interact by nuclear magnetic resonance (View
interaction).
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Rev1/polf-dependent TLS allows bypass replication acrossSites of DNA damage (lesions) encountered by replication
machinery in the process of cell division stall replication fork pro-
gression, threatening the survival of dividing cells. DNA damage
tolerance pathways provide the means to bypass DNA lesions
while temporarily leaving them unrepaired, thus rescuing replica-
tion from coming to a halt [1,2]. Bypass DNA replication in human
cells is carried out by low-ﬁdelity translesion synthesis (TLS)
polymerases, including Rev1, polg, poli, polj (Y-type) and polf
(B-type), which constitute a mutagenic branch of DNA damage tol-
erance [1,2]. Recent reports suggest that TLS enzymes also play a
role in postreplicational gap ﬁlling [3]. TLS polymerases represent
the primary source of mutations introduced into the genome, with
Rev1 and polf responsible for most damage-induced and spontane-
ous mutagenesis [4].chemical Societies. Published by E
, C-terminal domain of Rev1;
resonance; TROSY, transverse
ration calorimetry; aa, amino
ev).bulky DNA lesions such as N2-benzo[a]pyrene-dG and cisplatin ad-
ducts, or [4–6] photoproduct, involving the concerted action of
several TLS polymerases [5–8]. In this process the ‘inserter’ TLS en-
zyme replaces the replicative DNA polymerase (pold, pole) at
stalled replication fork in response to Rad6/Rad18-dependent
mono-ubiquitination of PCNA [9] and inserts a nucleotide across
from the lesion. Subsequently, the ‘inserter’ enzyme is replaced
by ‘extender’ TLS polymerase (most frequently polf) capable of
extending the distorted DNA primer terminus [5,6]. The recruit-
ment of TLS polymerases to sites of DNA damage and polymerase
switching upon DNA lesion bypass are mediated by a variety of
protein–protein interactions [2]. In spite of their major role in
TLS, the key interactions of TLS polymerases that govern the selec-
tion of lesion-speciﬁc enzymes, and determine the order of poly-
merase switching events are not yet structurally characterized.
Besides exhibiting limited catalytic activity, Rev1 serves as an
interaction platform for other major TLS polymerases, thereby
playing a key role in coordinating the TLS pathway [2]. Unlike
other Y-type polymerases, Rev1 possesses two unique interaction
domains: an N-terminal BRCT domain that binds PCNA and a
C-terminal domain (Rev1-CT) responsible for Rev1 interaction with
major TLS polymerases [2]. Speciﬁcally, in vertebrates the Rev1-CTlsevier B.V. All rights reserved.
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for binding polg, poli, polj and Rev7 subunit of polf [2,10]. Con-
siderable evidence suggests that Rev1 and polf (a complex of
accessory Rev7 and catalytic Rev3 subunits) act together in muta-
genic DNA lesion bypass [4,8]. Thus, cells deﬁcient in Rev1, Rev3 or
Rev7 proteins exhibit increased sensitivity to DNA damage and
substantially reduced rate of mutations [4]. It is notable that
Rev1 mutants lacking the C-terminal domain fail to complement
Rev1 deﬁciency [8], suggesting that protein–protein interactions
mediated by Rev1-CT are critical for Rev1/polf-dependent TLS.
Recently, we have determined the solution NMR structures of
human Rev1-CT domain (residues 1157–1251) alone and in com-
plex with one of the two Rev1-interacting regions (RIRs) from polg
(residues 524–539) (PDB: 2LSY,2LSK) [11]. The domain adopts a
four-helix bundle fold, with the binding site for polg-RIR formed
by theN-terminalb-hairpin and the following twoa-helices.Human
Y-type polymerases polg, poli, polj contain RIR-motifs including
two consecutive Phe residues that ﬁt into a hydrophobic pocket in
theN-terminal part of Rev1-CT [11,12], thus utilizing a similarmode
for Rev1-CT binding. Moreover, recently reported spatial structure
of mouse Rev1-CT in complex with polj-RIR [13] revealed that
polg and polj utilize identical modes of Rev1-CT binding, suggest-
ing that RIR-motifs of Y-type polymerases are likely to compete for
the same binding site on the Rev1-CT domain.
In contrast, no RIR-motifs have been identiﬁed in Rev7 subunit
of polf, indicating that its mode of Rev1-CT interaction is different
from that of polg, poli and polj. The crystal structure of human
Rev7 (R124A; PDB: 3ABD,3ABE) has been determined in complex
with a peptide from the catalytic subunit of polf, Rev3 (residues
1847–1898), and several residues of Rev7 involved in Rev1-CT
interaction have been identiﬁed by mutational analysis [14]. This
analysis revealed that Rev7 interacts with Rev1-CT and Rev3
through different interfaces and, therefore, can bind Rev1 and
Rev3 simultaneously. Here we use NMR spectroscopy (i) to map
previously undeﬁned Rev1-CT binding site for Rev7 subunit of polf,
(ii) to show that this site is distinct from Rev1-CT binding interface
for RIR-motifs of polg, i, j, and (iii) to demonstrate the possibility
of assembling quadruple Rev1-CT/(Rev7/Rev3)/polg-RIR complex
where Rev1-CT is bound to the fragments of polg and polf. These
results infer a possibility that Rev1-CT may serve as a scaffold that
simultaneously binds one of the ‘inserter’ Y-type polymerases,
polg, i or j, and the ‘extender’ polf, thus facilitating the assembly
of multi-polymerase complexes carrying out TLS.
2. Materials and methods
2.1. Protein expression and puriﬁcation
15N/13C/2H-labeled human Rev1-CT (11 kDa) was produced as
described elsewhere [11]. In brief, the protein was over-expressed
in E. coli BL21(DE3) cells transformed with pET-28b(+) vector har-
boring the Rev1-CT gene (residues 1158–1251 following cleavage
site for TEV protease). Cells were grown in 100% 2H2O M9 medium
using 15NH4Cl and U-13C/2H-glucose as the sole nitrogen and car-
bon sources, respectively, followed by protein puriﬁcation by
Ni2+-afﬁnity column, His-tag cleavage, and puriﬁcation on a HiLoad
Superdex-75 column.
The triple complex of 15N/13C/2H Rev1-CT(1158–1251) and
unlabeled Rev7(R124A)/Rev3(1847–1898) (below referred to as
Rev7/Rev3) was obtained by HiLoad Superdex-200 size-exclusion
puriﬁcation of a mixture of the Rev1-CT (11 kDa) and an excess
of Rev7/Rev3 (32 kDa), with subsequent collection of a peak
corresponding to Rev1-CT/Rev7/Rev3 assembly (43 kDa). His-
tagged Rev7(R124A) was co-expressed with Rev3(1847–1898) in
E. coli BL21(DE3) cells transformed with pETDuet-1 vector harbor-ing genes encoding both proteins [14]. Cells were grown on LB
medium, followed by protein puriﬁcation using Ni2+-afﬁnity and
HiLoad Superdex-200 columns.
The quadruple complex of 15N/13C/2H Rev1-CT(1158–1251),
unlabeled Rev7(R124A)/Rev3(1847–1898), and unlabeled
polg-RIR peptide (residues 524–539) was obtained by gradually
titrating a concentrated 25 mM solution of custom synthesized
(GenScript) peptide into Rev1-CT/Rev7/Rev3 sample. The ﬁnal
samples of triple Rev1-CT/Rev7/Rev3 (43 kDa) and quadruple
Rev1-CT/Rev7/Rev3/polg-RIR (44 kDa) complexes contained
0.4 mM protein, 50 mM NaH2PO4, 100 mM NaCl, 1 mM EDTA,
5 mM DTT, 0.05% NaN3, 10% D2O, pH = 7.0.
2.2. NMR spectroscopy
Nearly complete 1H/15N/13C NMR resonance assignments for the
free Rev1-CT and Rev1-CT/polg-RIR complex (15 C) were reported
elsewhere (BMRB: 18455,18434) [11]. The backbone 1HN, 15N, 13Ca
and 13CO assignments (35 C) for 15N/13C/2H Rev1-CT in complex
with unlabeled (i) Rev7/Rev3 and (ii) Rev7/Rev3/polg-RIR were ob-
tained in this work from a series of 2D 1H–15NHSQC, 1H–15N TROSY,
and 3D TROSY-HNCO, TROSY-HNCA and 15N-edited NOESY-HSQC
spectra [15,16] recorded on 18.8T Agilent VNMRS spectrometer
equipped with cold-probe.
The residues on Rev1-CT interaction interfaces with Rev7/Rev3
and polg-RIR were identiﬁed based on chemical shift changes for
the backbone nuclei upon the formation of the complexes. Specif-
ically, normalized chemical shift differences were calculated for
each residue [17]:
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where index i runs over N = 4 nuclei used for the comparison: 1HN,
15N, 13Ca and 13CO, D-i is chemical shift change for a nucleus i, -std,i
is nucleus/residue speciﬁc normalization value equal to 1 standard
deviation of chemical shift distribution in BMRB database
(www.bmrb.wisc.edu). The chemical shift differences,D-0, between
(i) Rev1-CT/polg-RIR complex and the free Rev1-CT (15 C), and be-
tween (ii) Rev1-CT/Rev7/Rev3/polg-RIR and Rev1-CT/Rev7/Rev3
complexes (35 C) were used to assess Rev1-CT – polg-RIR binding,
whileD-0 between (iii) Rev1-CT/Rev7/Rev3 complex and an isolated
Rev1-CT were used to map the Rev1-CT – Rev7 interaction interface.
For the later comparison we used 1HN and 15N chemical shifts
obtained at 20 C, assigned from a temperature series of 1H–15N
HSQC spectra recorded for the free domain and the complex, and
13Ca and 13CO shifts obtained at 15 C (free Rev1-CT) and 35 C
(Rev1-CT/Rev7/Rev3). Note that at temperatures above 20–25 C
spectra of the free Rev1-CT deteriorate due to ls-ms exchange
line-broadening [11].
15N R1 and R2 relaxation measurements for the 15N/13C/2H
Rev1-CT in complex with Rev7/Rev3 and Rev7/Rev3/polg-RIR
(35 C, 18.8T) were performed using the pulse-sequences of Farrow
et al. [18]. Overall rotation correlation times, sR, for the complexes
were calculated from 15N R2/R1 ratios for residues from regular sec-
ondary structure elements of Rev1-CT (a-helices H1-H4), and were
used to monitor the change in molecular size upon the formation of
the complexes. 15N relaxation measurements (15 C, 11.7T) and the
analysis of molecular overall rotation for the free Rev1-CT and
Rev1-CT/polg-RIR complex were reported previously [11].
2.3. Isothermal titration calorimetry
Rev1-CT - Rev7/Rev3 binding was additionally assessed by ITC
performed at 30 C using nano-ITC low-volume unit (TA Instru-
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Fig. 1. (A) Superposition of 1H–15N HSQC spectra (11.7T, 15 C) of the free 15N/13C Rev1-CT (black) and 15N/13C Rev1-CT complex with unlabeled polg-RIR peptide (green). (B)
Superposition of 1H–15N HSQC spectra (18.8T, 35 C) of 15N/13C/2H Rev1-CT complex with unlabeled Rev7/Rev3 recorded in the absence (red) and presence (blue) of polg-RIR
peptide. The shifts in peak positions upon Rev7 binding are shown with arrows for 9 Rev1-CT residues from the Rev7 binding site.
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Fig. 2. (A) 15N R1 and R2 rates for the free Rev1-CT (blue) and Rev1-CT/polg-RIR
complex (cyan) measured at 11.7T, 15 C; relaxation data for the triple
Rev1-CT/Rev7/Rev3 (red) and quadruple Rev1-CT/Rev7/Rev3/polg (green) com-
plexes obtained at 18.8T, 35 C. (B) Molecular weights (MW) and overall correlation
times, sR, estimated from 15N R2/R1 ratios (adjusted to 35 C) for Rev1-CT and its
complexes.
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tions of Rev1-CT into Rev7/Rev3 solution, samples were dissolved
in 50 mM NaH2PO4, 100 mM NaCl, 1 mM TCEP, pH = 7.0, ﬁltered,
concentrated to 0.94 mM (Rev1-CT) and 0.15 mM (Rev7/Rev3)
and degassed. The data were analyzed using NanoAnalyze
software (TA Instruments), resulting in association enthalpy
DH = -9.4 ± 0.1 kcal/M and dissociation constant KD = 1.3 ± 0.2 lM
for Rev1-CT – Rev7/Rev3 complex, which is an order of magnitude
stronger than KD = 8–69 lM reported for Rev1-CT interaction with
RIR-motifs from polg, poli, polj [12].
3. Results
3.1. Rev1-CT can simultaneously bind polg-RIR and Rev7
To test the hypothesis that relatively small Rev1-CT can simul-
taneously bind several human TLS DNA polymerases we have mon-
itored the formation Rev1-CT complexes with its interaction
partners by NMR spectroscopy. Fig. 1 shows 1H–15N HSQC spectra
of 11 kDa free Rev1-CT (black; plot A) and 43 kDa complex of
Rev1-CT with accessory Rev7 and a part of catalytic Rev3 subunits
of DNA polymerase polf (red; plot B). Rev1-CT forms a tight
complex with the Rev7/Rev3 construct used in this study (via
Rev7 subunit [14]) that elutes as a single peak from Superdex-
200 size-excision column, consistent with KD = 1.3 ± 0.2 lM
(30 C) obtained by ITC (see Methods and Supplementary data).
Not surprisingly, a number of resonances in 1H–15N HSQC spec-
trum changed their positions upon complex formation (arrows in
Fig. 1A and B), suggesting that an extensive region of Rev1-CT is in-
volved in interaction with Rev7. It is notable that a different set of
Rev1-CT resonances is sensitive to the binding of polg-RIR motif
(compare green and black spectra on Fig. 1A), pointing to the fact
that Rev1-CT utilizes different interfaces for interaction with polf
and Y-type polymerases polg, poli, polj.
To check if Rev7 competes with RIR-motifs of Y-type polymer-
ases for Rev1-CT binding we have performed the titration of
Rev1-CT/Rev7/Rev3 complex with polg-RIR peptide and moni-
tored chemical shift changes for the Rev1-CT in 1H–15N HSQC
spectra. Superposition of spectra of Rev1-CT/Rev7/Rev3 (red) and
Rev1-CT/Rev7/Rev3 - polg-RIR 1:1 mixture (blue) is shown on
Fig. 1B. Rev1-CT resonances that changed their positions upon
the formation of Rev1-CT/Rev7/Rev3 complex (arrows in Fig
1A,B) were essentially unaffected by the addition of polg-RIR pep-
tide, suggesting that polg-RIR motif is unable to displace Rev7
bound to Rev1-CT. On the other hand, a different set of Rev1-CT
peaks shifted to their new positions upon addition of polg-RIR
peptide to Rev1-CT/Rev7/Rev3 complex (compare blue and redspectra on Fig. 1B), corresponding to residues on the Rev1-CT –
polg-RIR binding interface identiﬁed in our previous study [11].
This ﬁnding suggests that binding to Rev7 cannot prevent
Rev1-CT from forming the complex with polg-RIR. Therefore, the
comparison of the spectrum of Rev1-CT/Rev7/Rev3 – polg-RIR
mixture with the spectra of Rev1-CT/Rev7/Rev3 complex,
Rev1-CT/polg-RIR complex and the free Rev1-CT (Fig 1) clearly
demonstrates the formation of the quadruple complex where
Rev1-CT domain is simultaneously bound to the Rev7 subunit of
polf and polg-RIR peptide.
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nied by a proportional slowing down of molecular overall rotation
we have performed 15N R1 and R2 relaxation measurements for
Rev1-CT bound to (i) Rev7/Rev3 subunits of polf, and (ii)
Rev7/Rev3 and polg-RIR peptide, and estimated overall rotation
correlation time, sR, for the complexes from 15N R2/R1 ratios.
Fig. 2 shows 15N R1 and R2 rates and calculated sR values
(adjusted to 35 C) for triple Rev1-CT/Rev7/Rev3 and quadruple
Rev1-CT/Rev7/Rev3/polg-RIR assemblies, along with correspond-
ing data obtained in our previous study for the free Rev1-CT and
Rev1-CT/polg-RIR complex [11]. As expected, increase in sR upon
the formation of the complexes closelymatches increase inmolecu-
lar size. This observation suggests that Rev1-CT in the context of
Rev7/Rev3 and Rev7/Rev3/polg-RIR tumbles as a part of larger
molecular complex rather than as an isolated 11 kDa domain.
3.2. Rev1-CT utilizes independent sites for interaction with polg and
Rev7
The residues of human Rev1-CT involved in interactions with its
partners were identiﬁed based on binding-induced changes in the
backbone 1HN, 15N, 13Ca, 13CO chemical shifts. The backbone reso-
nance assignments of the per-deuterated 15N/13C/2H Rev1-CT in
the context of 43 kDa triple complex with Rev7/Rev3 and 44 kDa
quadruple complex with Rev7/Rev3 and polg-RIR were obtained
from a set of TROSY-based triple-resonance NMR experimentsResidue
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Fig. 3. (A) Normalized chemical shift changes, D-0 (eq.1), for the backbone 1H, 15N, 13Ca
complexes with polg-RIR peptide. (B,C) Chemical shift differences, D-0 , between the free
(B) plotted vs. residue number and (C) mapped onto the structure of Rev1-CT bound to po
(D) 1H–1H strip-plots from 15N-edited NOESY-HSQC of 15N/13C/2H Rev1-CT in complex
deuterated Rev1-CT to 1H of aliphatic side-chains of Rev7 (red).[15]. The Rev-CT binding interfaces with different partners were
mapped by calculating normalized per-residue chemical shift dif-
ferences, D-0 (eq. 1), that reﬂect cumulative chemical shift change
for the backbone nuclei upon the complex formation [17]. Thus,
D-00 are expected in protein regions with no structural changes,
while D-01 reﬂect binding-induced conformational rearrange-
ments accompanied by signiﬁcant chemical shift variations.
Fig. 3A shows the comparison D-0 values between Rev1-CT and
its complex with polg-RIR peptide obtained in the absence (blue)
and presence of Rev7/Rev3 (green), while Fig. 3B displays D-0 for
Rev1-CT domain obtained upon binding Rev7/Rev3 (red) and
polg-RIR motif (blue) plotted vs. residue number. Fig. 3C also illus-
trates D-0 values mapped onto the Rev1-CT structure, outlining
the binding sites for Rev7 subunit of polf (red) and polg-RIR motif
(blue).
The structure of Rev1-CT in complexwith 16aa polg-RIR peptide
[11] revealed that polg-RIR binding site encompasses the N-termi-
nal b-hairpin, the end of a-helix H1, H1–H2 loop and the beginning
of a-helix H2. As expected, the residues in this region exhibit
noticeable chemical shift changes upon polg-RIR binding (Fig
3A,C). Very similar D-0 patterns are observed for polg-RIR binding
to an isolated Rev1-CT and to a triple Rev1-CT/Rev7/Rev3 complex
(Fig 3A), suggesting that the mode of Rev1-CT interaction with RIR-
motifs of Y-type polymerases is unaffected by Rev7 binding.
Chemical shift changes upon the formation of Rev1-CT –
Rev7/Rev3 complex suggest that two different non-overlapping re-40 1250
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Fig. 4. (A) TALOS + based [20] probability of a-helix, P(a), and b-sheet, P(b), and (B) RCI-based [21] backbone amide order parameters, S2, for the free Rev1-CT (red) and its
complexes with Rev7/Rev3 (blue) and Rev7/Rev3/polg-RIR (green) derived from the backbone chemical shifts. (C) Putative mode of Rev1-CT - Rev7/Rev3 binding based on
chemical shift analysis of Rev1-CT and its complexes. Regions of Rev1-CT exhibiting large chemical shifts changes, D-0 , upon Rev7 binding (Fig. 3) are shown in orange;
residues L1248, K1249 are shown as b-strand.
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(Fig. 3B,C). The Rev7 binding site of Rev1-CT encompasses (i) resi-
dues 1201–1204 from H2-H3 loop and the beginning of a-helix
H3, and (ii) residues 1241, 1244 and 1246–1251 from the end of
a-helixH4and theﬂexible C-terminal part of thedomain. These spa-
tially adjacent regions are located on the face of Rev1-CT opposite
the interaction site for RIR-motifs of Y-type polymerases (Fig. 3C),
allowing Rev1-CT to simultaneously bind fragments of two different
TLS enzymes. Involvement of the very C-terminus of Rev1-CT in
Rev7 binding is additionally conﬁrmed by NOE cross-peaks from
the backbone 1HN of T1247, K1259, V1250, T1251 of per-deuterated
Rev1-CT to 1H-nuclei of aliphatic side-chains of the unlabeled Rev7 in
15N-edited NOESY-HSQC spectrum of Rev1-CT/Rev7/Rev3/polg-RIR
complex (Fig. 3D). Interestingly, the sequence alignment of
Rev1-CT domains from different species identiﬁed a conserved re-
gion (referred to as rev1–112) in thedomainC-terminus [19], includ-
ing residues from the Rev7 interaction site identiﬁed in this work.
The residues 1201–1204 from H2-H3 loop and the beginning of
H3, displaying largeD-0 upon Rev7 binding, also belong to a region
conserved among eukaryotes, except S. cerevisiae and related yeasts
[19].
3.3. Rev7 binding triggers changes in Rev1-CT structure and dynamics
The chemical shifts of Rev1-CT and its complexes were used to
assess changes in secondary structure and conformational ﬂexibil-
ity of the domain upon binding its partners [20,21]. Fig. 4A shows
secondary structure of the isolated Rev1-CT and its complexes with
fragments of one (Rev7/Rev3) and two (Rev7/Rev3/polg) TLS poly-
merases predicted from the backbone chemical shifts by
TALOS+ [20], while Fig. 4B displays order parameters, S2, for the
backbone amide groups predicted by RCI [21], where S2 = 1(0) cor-
responds to restricted(unconstrained) dynamics. It is clear that
neither secondary structure nor backbone ﬂexibility of the domain
are affected by interaction with Rev7/Rev3 and/or polg-RIR, with
the exception of the C-terminal part (residues 1246–1251)
undergoing remarkable transformation upon Rev7 binding. This re-
gion, ﬂexible in isolated Rev1-CT, is stabilized in complexes with
Rev7/Rev3 and Rev7/Rev3/polg-RIR (Fig. 4B) and adopts an ex-
tended b-strand conformation (Fig. 4A). Previous mutational anal-
ysis identiﬁed b-strands b80 and b800 of Rev7 as interaction site for
Rev1-CT domain (Fig. 4C) [14]. Speciﬁcally, mutations of L186 of
b80 and Q200, Y202 of b800 on the outer surface of 5-stranded
b-sheet of Rev7 were shown to decrease Rev1-CT binding. Our re-
sults indicate that the C-terminal residues 1246–1251 of Rev1-CT
may provide an extension of the b-sheet of Rev7 by forming an
additional b-strand that interacts with b80 (Fig. 4C). On the otherhand, residues 1201–1204 from H2–H3 loop and a-helix H3 of
Rev1-CT, exhibiting pronounced chemical shift changes upon
Rev7 binding (Fig. 3B,C), may provide docking site for the outer
surface of the Rev7 b-sheet.
4. Discussion
In human cells TLS is carried out by at least 5 of 15 known DNA
polymerases, including low-ﬁdelity Y-family Rev1, polg, poli, polj
and B-family polf (Rev7/Rev3 complex) [1]. The access of these er-
ror-prone enzymes to DNA primer termini is strictly regulated
through multiple levels of protein–protein and protein-DNA inter-
actions [2]. The exchange of replicative to TLS DNA polymerases at
stalled replication forks is triggered by Rad6/Rad18-dependent
mono-ubiquitination of PCNA at K164 [9]. All eukaryotic Y-type
polymerases contain ubiquitin-binding UBM or UBZ domains [22]
in addition to the PCNA-interacting PIP-box motifs (or BRCT and
PAD domains in Rev1) that facilitate the ﬁrst polymerase exchange
[2]. Although some DNA lesions can be bypassed by a single TLS
enzyme, as exempliﬁed by efﬁcient and accurate bypass of TT-
CPDs (cyclobutane pyrimidine dimers) by polg [23], TLS across
most types of DNA damage involves the consecutive action of
two or more TLS polymerases [5–8], which necessitates further
polymerase switching events. Because of its ability to interact with
other major TLS polymerases via the C-terminal domain [10], Rev1
likely plays a key role in coordinating these polymerase exchange
events by helping match the ‘inserter’ polymerases polg, poli, polj
with their cognate DNA lesions and facilitating their subsequent
exchange to polf, which extends the distorted DNA primer
terminus.
The likely ‘inserters’ in two-polymerase TLS, polg, poli and
polj, interact with Rev1-CT via short RIR-motifs [11,12] that bind
the N-terminal part of Rev1-CT (Fig. 3C, blue). In this work we have
shown that the opposite face of Rev1-CT, involving the C-terminal
part of the domain, is responsible for Rev1 interaction with Rev7
(Fig. 3C, red). Consequently, we were able to reconstitute a quadru-
ple Rev1-CT/Rev7/Rev3/polg-RIR complex where Rev1-CT is
simultaneously bound to a fragment of the ‘inserter’ TLS polymer-
ase polg and Rev7 subunit of the ‘extender’ polymerase polf, mak-
ing it tempting to speculate that these interactions may also occur
in the context of full-size acting TLS polymerase complexes. This
ﬁnding is contrary to earlier reports suggesting that Rev7 competes
with Y-type polymerases for Rev1-CT binding [10]. The feasibility
of Rev1-CT/polg/polf complex formation would imply that DNA
lesion bypass performed by several TLS enzymes may occur with-
out polymerase dissociation with the aid of Rev1-CT domain,
which serves as a scaffold for the assembly of TLS polymerase com-
3056 Y. Pustovalova et al. / FEBS Letters 586 (2012) 3051–3056plexes where the ‘extender’ and ‘inserter’ enzymes are tied to-
gether and are instantaneously available for nucleotide insertion
across DNA lesion and extension from the distorted base-pair.
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